Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen.
Using a unique vaccine antigen matched and single HIV Clade C approach we have assessed the immunogenicity of a DNA-poxvirus-protein strategy in mice and rabbits, administering MVA and protein immunizations either sequentially or simultaneously and in the presence of a novel TLR4 adjuvant, GLA-AF. M...
Saved in:
| Main Authors: | Paul F McKay, Alethea V Cope, Jamie F S Mann, Sarah Joseph, Mariano Esteban, Roger Tatoud, Darrick Carter, Steven G Reed, Jonathan Weber, Robin J Shattock |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0084707 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.
by: Agricola Joachim, et al.
Published: (2016-01-01) -
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.
by: Rhea N Coler, et al.
Published: (2011-01-01) -
Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens.
by: Nathifa Moyo, et al.
Published: (2017-01-01) -
ISG15 as a Potent Immune Adjuvant in MVA-Based Vaccines Against Zika Virus and SARS-CoV-2
by: Juan García-Arriaza, et al.
Published: (2025-06-01) -
Improving the efficiency of the regulatory approvals of HIV in vitro diagnostics in low- and middle-income countries: Perspective of the IAS Industry Liaison Forum diagnostic partners.
by: Tammy Steuerwald, et al.
Published: (2025-01-01)